Acadia's Research Chief Elizabeth Thompson Is Out As An Employee, And Her Job Is Open
Acadia Pharmaceuticals is searching for a new head of research and development after Elizabeth Thompson's retirement took effect Friday.
Acadia Pharmaceuticals, the San Diego drugmaker behind the Parkinson's psychosis drug Nuplazid and the Rett syndrome drug Daybue, said Elizabeth H.Z. Thompson stopped working as its head of research and development on Friday, and it is still looking for her replacement.
A retirement that has now taken effect
Thompson, who holds a Ph.D. and was Acadia's executive vice president and head of research and development, told the company on April 27 that she planned to retire for personal reasons. Acadia first disclosed that plan in a Form 8-K, the report public companies file for major events, on May 1.
As of October 23, she is no longer an employee and no longer performs the research role, according to the company's latest filing. The company said it is in the process of identifying her replacement.
The same day, Acadia retained her as a consultant. She intends to provide limited consulting services through December 31, 2026.
A consulting deal with a caveat
The filing itself warns that Thompson could decide not to serve as a consultant. That makes the year-end runway an intention, not a commitment.
The departure leaves open the top research seat at a company whose pipeline is led by remlifanserin, a drug candidate for psychosis tied to Alzheimer's disease and Lewy Body Dementia.
Two drugs carry the business
Acadia develops and sells drugs for neurological and rare diseases. Nuplazid is approved by the US Food and Drug Administration for hallucinations and delusions associated with Parkinson's disease psychosis, while Daybue is approved for Rett syndrome and sold in the United States, with approvals also in Canada and Israel.
Net sales of the two products totaled $1,071.5 million in 2025, compared with $957.8 million in 2024, according to the company's annual report.
Thompson's consulting arrangement is slated to run through December 31, 2026, the date by which she intends to finish her limited services.
Sources
- 8-K Filing — ACADIA PHARMACEUTICALS INC (ACAD) — SEC EDGAR